Department of Gastroenterology and Hepatology, Amsterdam UMC, Vrije Universiteit Amsterdam, AGEM Institute, Amsterdam, the Netherlands.
Department of Pathology, Amsterdam UMC, Amsterdam, the Netherlands.
Clin Transl Gastroenterol. 2021 Aug 1;12(8):e00387. doi: 10.14309/ctg.0000000000000387.
Adult-onset autoimmune enteropathy (AIE) is a rare cause of severe chronic diarrhea because of small intestinal villous atrophy. We report on patients with adult-onset AIE in an European referral center.
Retrospective study including patients diagnosed with AIE in the Amsterdam UMC, location VUmc, between January 2003 and December 2019. Clinical, serological, and histological features and response to treatment were reported. The specificity of antienterocyte antibodies (AEA) was evaluated by examining the prevalence of AEA in (i) controls (n = 30) and in patients with (ii) AIE (n = 13), (iii) celiac disease (CD, n = 52), (iv) refractory celiac disease type 2 (n = 18), and (v) enteropathy-associated T-cell lymphoma (EATL, n = 10).
Thirteen AIE patients were included, 8 women (62%), median age of 52 years (range 23-73), and 6 (46%) with an autoimmune disease. AEA were observed in 11 cases (85%), but were also found in CD (7.7%), refractory celiac disease type 2 (16.7%), and EATL (20%). Ten patients (77%) were human leukocyte antigen DQ2.5 heterozygous. Total parenteral nutrition was required in 8 cases (62%). Steroids induced clinical remission in 8 cases (62%). Step-up therapy with rituximab, cyclosporine, infliximab, and cladribine in steroid-refractory patients was only moderately effective. Four patients died (31%), but 4 (31%) others are in long-term drug-free remission after receiving immunosuppressive treatment, including 1 patient who underwent autologous stem cell transplantation.
Adult-onset AIE is a rare but severe enteropathy that occurs in patients susceptible for autoimmune disease. Four patients (31%) died secondary to therapy-refractory malabsorption, while immunosuppressive therapy leads to a long-lasting drug-free remission in one-third of patients.
成人发病的自身免疫性肠病(AIE)是一种罕见的因小肠绒毛萎缩导致严重慢性腹泻的原因。我们报告了在欧洲转诊中心的成人发病 AIE 患者。
回顾性研究包括 2003 年 1 月至 2019 年 12 月在阿姆斯特丹 UMC,VUmc 院区诊断为 AIE 的患者。报告了临床、血清学和组织学特征以及治疗反应。通过检查抗肠细胞抗体(AEA)在(i)对照组(n=30)和(ii)AIE(n=13)、(iii)乳糜泻(CD,n=52)、(iv)难治性 CD 型 2(n=18)和(v)肠病相关 T 细胞淋巴瘤(EATL,n=10)中的患病率,评估了 AEA 的特异性。
纳入 13 例 AIE 患者,8 例女性(62%),中位年龄 52 岁(范围 23-73),6 例(46%)合并自身免疫性疾病。11 例(85%)存在 AEA,但在 CD(7.7%)、难治性 CD 型 2(16.7%)和 EATL(20%)中也有发现。10 例患者(77%)为人白细胞抗原 DQ2.5 杂合子。8 例(62%)需要全肠外营养。8 例(62%)患者用类固醇诱导临床缓解。在类固醇难治性患者中,用利妥昔单抗、环孢素、英夫利昔单抗和克拉屈滨进行逐步治疗的效果仅为中等。4 例患者死亡(31%),但 4 例(31%)患者在接受免疫抑制治疗后无药物长期缓解,其中 1 例患者接受了自体干细胞移植。
成人发病的 AIE 是一种罕见但严重的肠病,发生在易患自身免疫性疾病的患者中。4 例患者(31%)因治疗难治性吸收不良而死亡,而免疫抑制治疗可使三分之一的患者无药物长期缓解。